Baird raised the firm’s price target on Privia Health to $24 from $23 and keeps an Outperform rating on the shares. The firm updated its estimates following the company’s most recently reported results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: